MedTrace Logo

Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain

NCT04666714 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2025-03-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Praga formulation in the treatment of neuropathic pain.

Conditions

  • Neuropathic Pain

Interventions

DRUG

Praga formulation

Praga formulation tablet

OTHER

Placebo pregabalin 75mg

Placebo pregabalin 75mg tablet

OTHER

Placebo Pregabalin 150mg

Placebo Pregabalin 150mg tablet

DRUG

Pregabalin 75mg

Pregabalin 75mg tablet

DRUG

Pregabalin 150mg

Pregabalin 150mg tablet

OTHER

Placebo Praga formulation

Placebo Praga formulation tablet

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04666714 on ClinicalTrials.gov